CA3149104A1 - Micromolecule pi4kiiia inhibitor composition, preparation method therefor and use thereof - Google Patents
Micromolecule pi4kiiia inhibitor composition, preparation method therefor and use thereof Download PDFInfo
- Publication number
- CA3149104A1 CA3149104A1 CA3149104A CA3149104A CA3149104A1 CA 3149104 A1 CA3149104 A1 CA 3149104A1 CA 3149104 A CA3149104 A CA 3149104A CA 3149104 A CA3149104 A CA 3149104A CA 3149104 A1 CA3149104 A1 CA 3149104A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition according
- pao
- oil
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/094831 | 2019-07-05 | ||
| CN2019094831 | 2019-07-05 | ||
| PCT/CN2020/100377 WO2021004422A1 (zh) | 2019-07-05 | 2020-07-06 | 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3149104A1 true CA3149104A1 (en) | 2021-01-14 |
Family
ID=74115038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3149104A Pending CA3149104A1 (en) | 2019-07-05 | 2020-07-06 | Micromolecule pi4kiiia inhibitor composition, preparation method therefor and use thereof |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685566A (zh) * | 2020-12-31 | 2022-07-01 | 江苏挪贝肽医药科技有限公司 | 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法 |
| MX2024004055A (es) * | 2021-09-30 | 2024-06-19 | Nuo Beta Pharmaceutical Tech Shanghai Co Ltd | Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo. |
| CN116478954B (zh) * | 2023-02-14 | 2025-06-10 | 中国农业大学 | 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002365110A1 (en) * | 2001-07-10 | 2003-07-15 | Massachusetts Institute Of Technology | Small molecule microarrays |
| EP2319926B1 (en) * | 2007-07-05 | 2016-08-31 | Arrowhead Research Corporation | DSRNA for treating viral infection |
| WO2016172952A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用 |
| WO2019200043A1 (en) * | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
| EP4130014A4 (en) * | 2020-03-31 | 2024-05-15 | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | Deuterated oxophenylarsine compound and use thereof |
| MX2024004055A (es) * | 2021-09-30 | 2024-06-19 | Nuo Beta Pharmaceutical Tech Shanghai Co Ltd | Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo. |
-
2020
- 2020-07-03 TW TW109122503A patent/TW202126294A/zh unknown
- 2020-07-06 EP EP20836327.5A patent/EP3995134A4/en active Pending
- 2020-07-06 CN CN202080049288.5A patent/CN114555056B/zh active Active
- 2020-07-06 WO PCT/CN2020/100377 patent/WO2021004422A1/zh not_active Ceased
- 2020-07-06 JP JP2022526849A patent/JP2022538505A/ja active Pending
- 2020-07-06 AU AU2020309681A patent/AU2020309681A1/en not_active Abandoned
- 2020-07-06 CN CN202311755839.1A patent/CN118105372A/zh active Pending
- 2020-07-06 CA CA3149104A patent/CA3149104A1/en active Pending
- 2020-07-06 PE PE2022000005A patent/PE20220942A1/es unknown
- 2020-07-06 US US17/624,850 patent/US20230115711A1/en not_active Abandoned
- 2020-07-06 MX MX2022000287A patent/MX2022000287A/es unknown
- 2020-07-06 BR BR112022000155A patent/BR112022000155A2/pt not_active Application Discontinuation
- 2020-07-06 KR KR1020227003749A patent/KR20220071175A/ko not_active Ceased
- 2020-07-06 PH PH1/2022/550254A patent/PH12022550254A1/en unknown
-
2022
- 2022-01-03 IL IL289586A patent/IL289586A/en unknown
- 2022-02-07 CO CONC2022/0001218A patent/CO2022001218A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220071175A (ko) | 2022-05-31 |
| CN118105372A (zh) | 2024-05-31 |
| EP3995134A4 (en) | 2023-07-12 |
| WO2021004422A1 (zh) | 2021-01-14 |
| JP2022538505A (ja) | 2022-09-02 |
| IL289586A (en) | 2022-03-01 |
| EP3995134A1 (en) | 2022-05-11 |
| CN114555056B (zh) | 2024-01-05 |
| TW202126294A (zh) | 2021-07-16 |
| AU2020309681A1 (en) | 2022-02-24 |
| BR112022000155A2 (pt) | 2022-04-12 |
| PE20220942A1 (es) | 2022-05-31 |
| US20230115711A1 (en) | 2023-04-13 |
| CO2022001218A2 (es) | 2022-05-20 |
| PH12022550254A1 (en) | 2023-06-26 |
| MX2022000287A (es) | 2022-06-16 |
| CN114555056A (zh) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2866067C (en) | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia | |
| KR101651448B1 (ko) | 체지방을 국소적으로 증가시키는 방법 및 조성물 | |
| CN114980890B (zh) | 可注射长效镇痛药物组合物及其制备方法和用途 | |
| US20230115711A1 (en) | MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| KR20140030122A (ko) | 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 | |
| WO2022160970A1 (zh) | 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液 | |
| DK2528598T3 (en) | RELATIONS TO suppress PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | |
| US11707467B2 (en) | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use | |
| AU2019271812A1 (en) | Pharmaceutical composition of KOR receptor agonist | |
| CN108310390B (zh) | 多西他赛亚油酸酯及其脂肪乳剂和应用 | |
| WO2015110040A1 (zh) | 苯丁酸氮芥衍生物、制备方法及应用 | |
| HK40073830A (en) | Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof | |
| OA20568A (en) | Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof. | |
| HK40074190B (en) | MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| HK40074190A (en) | MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| CN109985004A (zh) | 氟比洛芬酯脂肪乳注射液、其制备方法及应用 | |
| KR20150030725A (ko) | 계피유 및 그의 주성분 신남 알데히드로 제조된 항폐암 약물 및 그의 용도 | |
| CN116617203B (zh) | 一种自乳化微乳组合物及其制备方法和应用 | |
| CN115531306B (zh) | 一种注射用左奥硝唑衍生物乳状制剂及其制备方法 | |
| CN120004750B (zh) | 一种无菌的双他喷他多癸二酸酯及其制备方法与用途 | |
| CN120058608B (zh) | 可用于长效注射剂的喷他佐辛前药及制备方法与用途 | |
| JP7571940B2 (ja) | イブプロフェンエステル誘導体およびその乳状製剤 | |
| CA2880399C (en) | Use of bimatoprost free acid administered to the skin to reduce adipose tissue | |
| CN112755196B (zh) | 多奈哌齐离子液体 | |
| CN101016322A (zh) | 齐多夫定碳酸胆固醇酯的制备方法及其制剂和分析方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240705 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240705 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241115 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250106 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251204 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251222 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260306 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260407 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20260407 |